These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38814607)

  • 21. Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention.
    Li Q; Li H; Liu Z; Duan L
    Tohoku J Exp Med; 2024 Mar; 262(2):115-124. PubMed ID: 37821386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
    Bikdeli B; Erlinge D; Valgimigli M; Kastrati A; Han Y; Steg PG; Stables RH; Mehran R; James SK; Frigoli E; Goldstein P; Li Y; Shahzad A; Schüpke S; Mehdipoor G; Chen S; Redfors B; Crowley A; Zhou Z; Stone GW
    Circulation; 2023 Oct; 148(16):1207-1219. PubMed ID: 37746717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
    Valgimigli M; Frigoli E; Leonardi S; Rothenbühler M; Gagnor A; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Presbitero P; Santarelli A; Sardella G; Varbella F; Tresoldi S; de Cesare N; Rigattieri S; Zingarelli A; Tosi P; van 't Hof A; Boccuzzi G; Omerovic E; Sabaté M; Heg D; Jüni P; Vranckx P;
    N Engl J Med; 2015 Sep; 373(11):997-1009. PubMed ID: 26324049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial.
    Venetsanos D; Sederholm Lawesson S; Fröbert O; Omerovic E; Henareh L; Robertsson L; Linder R; Götberg M; James S; Alfredsson J; Erlinge D; Swahn E
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):502-509. PubMed ID: 30351167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safety and efficacy of bivalirudin versus unfractionated heparin during perioperative period of percutaneous coronary intervention].
    Li J; Cheng L; Wang HY; Zhao X; Liang ZY; Han YL; Li Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):648-654. PubMed ID: 32847320
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.
    Chen H; Yu X; Kong X; Li L; Wu J; Ma L
    J Int Med Res; 2020 Sep; 48(9):300060520947942. PubMed ID: 32985292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R; Eftychiou C; Somers K; Liu A; Burton-Wood N; Anderson M; Makri L; Blaxill J; McLenachan J; Wheatcroft S; Greenwood J; Blackman D
    EuroIntervention; 2013 May; 9(1):118-24. PubMed ID: 23410540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
    Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Bivalirudin-Associated Major Adverse Cardiac and Hemorrhagic Events in Acute Coronary Syndrome Patients on Chronic Dialysis Following Percutaneous Coronary Intervention.
    Fu D; Liu M; Gao T; Li C; Liao J; Shao M; Xiao X; Yang P; Li X; Jiang H
    J Invasive Cardiol; 2021 Nov; 33(11):E877-E883. PubMed ID: 34653957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
    French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
    Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
    Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.